INSTITUTO DE INVESTIGACIÓN BIOMÉDICA DE SALAMANCA
Instituto
VU University Medical Center
Ámsterdam, HolandaPublicaciones en colaboración con investigadores/as de VU University Medical Center (67)
2024
2023
-
Integrating biological HLA-DPB1 mismatch models to predict survival after unrelated hematopoietic cell transplantation
Haematologica
-
Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
HemaSphere, Vol. 7, Núm. 9, pp. E942
-
Multiparameter flow cytometry in the evaluation of myelodysplasia: Analytical issues: Recommendations from the European LeukemiaNet/International Myelodysplastic Syndrome Flow Cytometry Working Group
Cytometry Part B - Clinical Cytometry, Vol. 104, Núm. 1, pp. 27-50
2022
-
Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey
Blood, Vol. 140, Núm. 26, pp. 2773-2787
-
Comparison of outcomes for HLA-matched sibling and haplo-identical donors in Myelodysplastic syndromes: report from the chronic malignancies working party of EBMT
Blood Cancer Journal, Vol. 12, Núm. 9
-
Effects of copy number variations on brain structure and risk for psychiatric illness: Large-scale studies from the ENIGMA working groups on CNVs
Human Brain Mapping, Vol. 43, Núm. 1, pp. 300-328
-
Prognostic value of CPSS cytogenetic risk classification in patients with CMML after allogeneic hematopoietic cell transplantation: a retrospective multicenter study of the Chronic Malignancies Working Party of the EBMT
Bone Marrow Transplantation
2021
-
COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)
Journal of Hematology and Oncology, Vol. 14, Núm. 1
-
Flow cytometric analysis of myelodysplasia: Pre-analytical and technical issues—Recommendations from the European LeukemiaNet
Cytometry Part B - Clinical Cytometry
-
Methodological designs applied in the development of computer-based training programs for the cognitive rehabilitation in people with mild cognitive impairment (MCI) and mild dementia. Systematic review
Journal of Clinical Medicine, Vol. 10, Núm. 6, pp. 1-22
-
Primary refractory follicular lymphoma: a poor outcome entity with high risk of transformation to aggressive B cell lymphoma
European Journal of Cancer, Vol. 157, pp. 132-139
-
Total body irradiation + fludarabine compared to busulfan + fludarabine as “reduced-toxicity conditioning” for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT
Bone Marrow Transplantation, Vol. 56, Núm. 2, pp. 481-491
-
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome
Leukemia, Vol. 35, Núm. 6, pp. 1745-1750
2020
-
Core outcome set measurement for future clinical trials in acute myeloid leukemia: The HARMONY study protocol using a multi-stakeholder consensus-based Delphi process and a final consensus meeting
Trials, Vol. 21, Núm. 1
-
Dose response of the 16p11.2 distal copy number variant on intracranial volume and basal ganglia
Molecular Psychiatry, Vol. 25, Núm. 3, pp. 584-602
-
EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
ESMO Open, Vol. 5, Núm. 1
2019
-
Insights on Multiple Myeloma Treatment Strategies
HemaSphere, Vol. 3, Núm. 1
-
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
The Lancet Oncology, Vol. 20, Núm. 6, pp. e302-e312
-
Optimized EBMT transplant-specific risk score in myelodysplastic syndromes after allogeneic stem-cell transplantation
Haematologica, Vol. 104, Núm. 5, pp. 929-936